Coronary/Structural Heart

Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum

Coronary/Structural Heart by 0 comments

NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) — Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced plans to host a virtual event, “A Clinician’s Perspective: Holistic Approach to Managing PKP2-Associated Arrhythmogenic Cardiomyopathy,” at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum on Tuesday, December 9th at 3 PM ET. The session will feature a discussion with Dr. Victoria Parikh, M.D., who is Associate Professor of Cardiovascular Medicine at Stanford University and Director of the Stanford Center for Inherited Cardiovascular Disease, and an expert clinician scientist who cares for people living with PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM). Analysts and investors can join the live event by registering on the News & Events page on Lexeo’s website. A replay will be archived on the investor section of Lexeo’s website following the event. About Lexeo TherapeuticsLexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. The Company is advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including LX2006 in Friedreich ataxia (FA), LX2020 in plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need. Media Response:Media@lexeotx.com Investor Response:Carlo Tanzi, Ph.D.ctanzi@kendallir.com

Continue Reading →

Elucid Gains Broad CMS Reimbursement of Coronary Plaque Analysis Using PlaqueIQ™

Coronary/Structural Heart by 0 comments

New CPT I Code, OPPS and MPFS Decisions Recognize Significant Clinical Value Across Care Settings BOSTON–(BUSINESS WIRE)–Elucid has announced new Hospital Outpatient Prospective Payment (OPPS) and Physician Fee Schedule (PFS) decisions from the U.S. Centers for Medicare & Medicaid Services (CMS) that establish significant reimbursement for coronary plaque analysis using PlaqueIQ […]

Continue Reading →

Picard Medical, Inc. and SynCardia Systems LLC CEO to Present at CSI Focus D-HF 2025 in Frankfurt, Germany

Coronary/Structural Heart by 0 comments

TUCSON, Ariz., Dec. 03, 2025 (GLOBE NEWSWIRE) — Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Patrick NJ Schnegelsberg, CEO will attend and present data on the fully implantable Emperor Total Artificial Heart (TAH) at the upcoming CSI Focus D-HF (Device Therapies in Heart Failure) conference, scheduled for December 5th through 6th, 2025 in Frankfurt, Germany.

Continue Reading →

SCAI and CRT Announce Partnership to Advance Interventional Cardiology Education, Advocacy, and Research

Coronary/Structural Heart Financial by 0 comments

WASHINGTON—The Society for Cardiovascular Angiography & Interventions (SCAI) and Cardiovascular Research Technologies (CRT) today announce a new collaboration to elevate the field of interventional cardiology through shared education programming, legislative activities, and future research initiatives. As part of the collaboration, CRT is offering SCAI members discounted registration for CRT 2026, […]

Continue Reading →

Cleerly Unveils PowerScribe Integration and Lesion-Level Reporting at RSNA 2025

Coronary/Structural Heart by 0 comments

DENVER–(BUSINESS WIRE)–Cleerly, a leader in AI-based cardiovascular imaging, will showcase new product updates at RSNA 2025, November 30 – December 4, 2025, at McCormick Place in Chicago, IL. At Booth #8039, Cleerly will demonstrate PowerScribe integration and newly added lesion-level reporting, discuss new clinical research findings, and provide guidance on the […]

Continue Reading →

Validation study for EchoSolv HF completed at the Mayo Clinic – Study delivers exceptional results

Coronary/Structural Heart Radiology by 0 comments

SYDNEY, Nov. 24, 2025 (GLOBE NEWSWIRE) — AI and Medical Technology Company Echo IQ Limited (ASX: EIQ) (“Echo IQ” or “the Company”) is pleased to advise that it has completed its clinical validation for its heart failure clinical decision support software (“EchoSolv HF”) in collaboration with the Mayo Clinic Platform (“MCP”), a division of the Mayo Clinic, a top ranked US hospital. The MCP Validate program is a unique in-market AI evaluation program which generates an independent and objective report on accuracy, efficacy and susceptibility to bias for AI-based decision software (refer ASX Announcement 1 July 2025).

Continue Reading →

JenaValve Announces New, Late-Breaking Results from the ALIGN-AR Trial Published in The Lancet and Presented at PCR London Valves

Coronary/Structural Heart by 0 comments

IRVINE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced results from an expanded cohort of 700 patients from the ALIGN-AR pivotal trial for the Trilogy THV System in high-risk patients with symptomatic, severe aortic regurgitation (AR). These results were published in The Lancet and simultaneously presented as part of the Late-Breaking Clinical Trial sessions at PCR London Valves.

Continue Reading →

ConcertAI Introduces TeraRecon AV™, Advancing AI-Powered Medical Imaging with New Structural Heart and SaaS Capabilities

Coronary/Structural Heart by 0 comments

TeraRecon AV™ delivers advanced imaging visualization with AI-driven automations, enhancing clinician diagnostic precision and patient care while reducing manual efforts. It introduces advanced structural heart imaging simulations in a single solution, including Transcatheter Tricuspid Valve Replacement (TTVR), Transcatheter Mitral Valve Repair (TMVR), and Advanced Left Atrial Appendage (LAA) procedures, along […]

Continue Reading →

November Issue of Journal of Cardiac Failure-Intersections Highlights Advances in Right Ventricular Reserve, Revascularization Strategies, and LVAD Deactivation

Coronary/Structural Heart by 0 comments

The second issue of the open-access journal showcases multidisciplinary heart failure research and the many intersections that shape patient care. WASHINGTON, Nov. 19, 2025 /PRNewswire/ — The second issue of the Journal of Cardiac Failure-Intersections, online now, delivers a diverse…

Continue Reading →
1 2 3 4 5 … 419